CLINICAL TRIALS AND OBSERVATIONS Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
نویسندگان
چکیده
Renato Bassan,1 Orietta Spinelli,1 Elena Oldani,1 Tamara Intermesoli,1 Manuela Tosi,1 Barbara Peruta,1 Giuseppe Rossi,2 Erika Borlenghi,2 Enrico M. Pogliani,3 Elisabetta Terruzzi,3 Pietro Fabris,4 Vincenzo Cassibba,4 Giorgio Lambertenghi-Deliliers,5 Agostino Cortelezzi,5 Alberto Bosi,6 Giacomo Gianfaldoni,6 Fabio Ciceri,7 Massimo Bernardi,7 Andrea Gallamini,8 Daniele Mattei,8 Eros Di Bona,9 Claudio Romani,10 Anna Maria Scattolin,11 Tiziano Barbui,1 and Alessandro Rambaldi1
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials
Although levels of minimal residual disease (MRD) decrease below the detection limit in most adult patients with standardrisk acute lymphoblastic leukemia (ALL) after consolidation treatment, about 30% of these patients will ultimately relapse. To evaluate the power of MRD monitoring as an indicator of impending relapse, we prospectively analyzed postconsolidation samples of 105 patients enroll...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL
We performed sensitive polymerase chain reaction–based minimal residual disease (MRD) analyses on bone marrow samples at 9 follow-up time points in 71 children with T-lineage acute lymphoblastic leukemia (T-ALL) and compared the results with the precursor B-lineage ALL (B-ALL) results (n 210) of our previous study. At the first 5 follow-up time points, the frequency of MRD-positive patients and...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy
Data on minimal residual disease (MRD) monitoring in acute promyelocytic leukemia (APL) are available only in the context of conventional all-trans retinoic acid plus chemotherapy regimens. It is recognized that the kinetics of leukemia clearance is different with the use of arsenic trioxide (ATO) in the treatment of APL. We undertook a prospective peripheral blood RT-PCR–based MRD monitoring s...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
By using rapid flow cytometric techniques capable of detecting one leukemic cell in 104 normal cells, we prospectively studied minimal residual disease (MRD) in 195 children with newly diagnosed acute lymphoblastic leukemia (ALL) in clinical remission. Bone marrow aspirates (n 5 629) were collected at the end of remission induction therapy and at 3 intervals thereafter. Detectable MRD (ie, >0.0...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early molecular response to posttransplantation imatinib determines outcome in MRD Philadelphia-positive acute lymphoblastic leukemia (Ph ALL)
In adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph ALL), minimal residual disease (MRD) after stem cell transplantation (SCT) is associated with a relapse probability exceeding 90%. Starting imatinib in the setting of MRD may decrease this high relapse rate. In this prospective multicenter study, 27 Ph ALL patients received imatinib upon detection of MRD after SCT. Bcr-a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2009